Although many clinical trials have been reported on immunotherapy using PD-1 and PD-L1 inhibitors to treat HCC, to our knowledge, the relationship between treatment outcomes of immunotherapy for HCC with clinico-pathological characteristics of patients has not been evaluated systematically. The gene discussed is CD274; the disease is hepatocellular carcinoma.